In a groundbreaking study that promises to transform our understanding of neonatal endocrinology, researchers have identified significant elevations of corticosterone and 17-hydroxyprogesterone (17OH progesterone) in extremely preterm infants. This discovery unveils new facets of the stress response and steroidogenesis in the most vulnerable neonatal population—those born before 28 weeks of gestation. The implications reach far beyond basic science, hinting at potential clinical interventions and biomarker developments that could reshape neonatal care worldwide.

Extremely preterm infants face a unique spectrum of physiological challenges immediately after birth, owing to the immaturity of their organ systems and the abrupt transition from the intrauterine environment. The hypothalamic-pituitary-adrenal (HPA) axis, critical for stress regulation and metabolic adaptation, is particularly underdeveloped. This immaturity has spurred investigations into the roles of adrenal steroids like cortisol and its precursors in modulating their response to perinatal stressors. The recent findings provide compelling evidence that corticosterone, a glucocorticoid synthesized in the adrenal cortex, along with 17OH progesterone, an important steroidogenic intermediate, are markedly elevated in these neonates.

The elevation of corticosterone in extremely preterm infants contrasts with the traditional focus on cortisol as the principal glucocorticoid of interest in human neonates. Corticosterone’s functional role in humans has often been overshadowed by cortisol, yet this study illuminates its potential significance in the context of extreme prematurity. Measured through highly sensitive assays, the elevated corticosterone levels may reflect an alternative or compensatory pathway of glucocorticoid synthesis, possibly compensating for the immature enzymatic machinery that regulates steroidogenesis in these infants.

.adsslot_9XtwD0Wyxi{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_9XtwD0Wyxi{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_9XtwD0Wyxi{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Similarly, the surge in 17OH progesterone, typically considered a precursor in the biosynthesis of cortisol and androgens, uncovers critical insights into fetal adrenal metabolism. Elevated levels of this intermediate steroid could indicate a bottleneck in downstream enzymatic conversions, such as 21-hydroxylase or 11β-hydroxylase activity, which are essential for cortisol production. This enzymatic immaturity might underlie a unique steroidogenic phenotype in preterm infants, with potential implications for hormone-driven physiological adaptations during infancy.

The clinical ramifications of these hormonal alterations are profound. Corticosterone and 17OH progesterone elevations may serve not only as biomarkers of stress and adrenal function but also as predictors of neonatal outcomes. For instance, altered glucocorticoid levels have been linked to neurodevelopmental trajectories, immune system modulation, and vulnerability to chronic lung disease in preterm populations. Thus, understanding these hormonal profiles could inform risk stratification and personalized therapeutic strategies.

One of the pivotal challenges in neonatal medicine has been the management of adrenal insufficiency in extremely preterm infants. Conventional hormone replacement therapies often rely on cortisol measurements, but this study suggests that corticosterone might need equal consideration. The insights gained could reshape approaches to adrenal support, advocating for tailored glucocorticoid therapies that take into account the full steroidogenic spectrum rather than cortisol alone.

This research also advances our understanding of the HPA axis maturation in human neonates. Unlike in full-term infants, where the cortisol response is well characterized, the regulatory dynamics involving corticosterone and 17OH progesterone in preterms reveal complexities that have been underappreciated. The interplay of enzymatic activity, adrenal responsiveness, and negative feedback mechanisms in these infants is evidently distinct, prompting a reevaluation of neonatal endocrinology paradigms.

Moreover, the methodology employed to quantify these steroids demonstrates cutting-edge analytical precision. Utilizing mass spectrometry and advanced chromatographic techniques, the researchers overcame previous technical limitations that hindered accurate assessment of low-abundance steroids in neonatal blood samples. This technical leap forwards not only ensures reliability in current findings but sets a new standard for future endocrinological investigations in neonatal care.

The temporal pattern of steroid elevation is particularly intriguing. The researchers observed that corticosterone and 17OH progesterone levels exhibit dynamic changes in the immediate postnatal period, reflecting both acute stress responses and the evolving functionality of the adrenal gland. Tracking these changes longitudinally may reveal critical windows for intervention or monitoring to optimize neonatal outcomes.

Equally important is the potential interplay between these hormones and inflammatory mediators. Preterm infants frequently encounter systemic inflammation due to infections or mechanical ventilation. Elevated glucocorticoid precursors could interact with cytokine signaling pathways, influencing the neonatal immune response and possibly modulating susceptibility to sepsis or chronic inflammatory conditions.

This study also opens avenues for exploring the genetic and epigenetic regulation of adrenal steroidogenesis in preterm infants. Variations in genes encoding steroidogenic enzymes might correlate with observed hormonal profiles, offering insights into individualized susceptibility to adrenal dysfunction. Epigenetic modifications induced by prenatal stressors or intrauterine environmental factors could further modulate these pathways, contributing to the heterogeneity of clinical presentations.

In the broader context of neonatal medicine, identifying reliable biomarkers such as corticosterone and 17OH progesterone is invaluable. They hold promise for earlier diagnosis of adrenal insufficiency, enabling timely and targeted interventions that could mitigate morbidity and mortality. Future clinical trials may investigate whether modulating these steroid levels pharmacologically improves outcomes such as respiratory function, growth parameters, and neurodevelopment.

Furthermore, these findings challenge the existing neonatal treatment protocols, specifically concerning glucocorticoid administration. The standard use of hydrocortisone or dexamethasone might be reconsidered in light of a more nuanced understanding of endogenous steroid patterns. A more precise hormonal profile could guide safer dosing regimens, reducing side effects such as impaired growth or neurotoxicity.

The study also underscores the critical need for multidisciplinary collaboration, blending neonatology, endocrinology, pharmacology, and advanced biochemical analytics. Only by converging expertise can comprehensive insights into such multifaceted neonatal problems be attained and translated into clinical practice effectively.

Ultimately, this research heralds a paradigm shift in our conceptualization of neonatal stress physiology and adrenal function. By shedding light on the elevations of corticosterone and 17OH progesterone in extremely preterm infants, it lays the groundwork for innovative clinical approaches and enriches the scientific discourse surrounding fetal-to-neonatal transition.

As science continues to unravel the complexities of neonatal endocrinology, studies like this illuminate new paths toward improving the care and survival of preterm infants. While the journey from bench to bedside remains challenging, these findings invigorate hope for optimized interventions tailored to the unique physiological needs of the tiniest patients.

The quest to understand how these steroid hormones influence immediate and long-term health outcomes remains ongoing, driving further research that integrates clinical observations with molecular mechanisms. The implications extend beyond neonatology, potentially informing adult endocrinology and stress biology, given the foundational nature of early life hormone regulation.

In conclusion, the elevation of corticosterone and 17OH progesterone in extremely preterm infants represents a pivotal discovery with significant clinical and scientific ramifications. It challenges existing notions and fosters a deeper appreciation of neonatal adrenal physiology, opening doors to improved diagnostic precision, personalized treatment protocols, and ultimately, better survival and quality of life for preterm infants globally.

Subject of Research: Elevated levels of corticosterone and 17OH progesterone in extremely preterm infants and their clinical implications.

Article Title: Elevation of corticosterone and 17OH progesterone in extremely preterm infants and clinical implications.

Article References:

Kessel, J.M., Held, P.K., Bialk, E.R. et al. Elevation of corticosterone and 17OH progesterone in extremely preterm infants and clinical implications.
Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04216-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04216-5

Tags: 17OH progesterone significanceadrenal steroids in neonatal carebiomarkers for neonatal stressclinical implications of corticosteronecorticosterone levels in preterm infantsextremely preterm infant physiologyglucocorticoids in human infantsHPA axis development in neonatesneonatal care advancementsneonatal endocrinology researchsteroidogenesis in early lifestress response in preterm infants